Royalty Pharma's total assets for Q3 2024 were $18.04B, an increase of 2.18% from the previous quarter. RPRX total liabilities were $7.78B for the fiscal quarter, a -1.53% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.